Evidence map›Paper›PMID 23289497›Full record

ArticleTropical medicine & international health : TM & IH2013

Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.

Peter K Mudiope, Soyeon Kim, Deo Wabwire, Louis Nyende, Danstan Bagenda, Mike Mubiru, Robinah Mulira, Sawsan Elbireer, Zikulah Namukwaya, Mary Glenn Fowler and 1 more

Abstract readComparative Study
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peter K MudiopeMakerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda. pmudiope@mujhu.org
Soyeon Kim
Deo Wabwire
Louis Nyende
Danstan Bagenda
Mike Mubiru
Robinah Mulira
Sawsan Elbireer
Zikulah Namukwaya
Mary Glenn Fowler
Philippa Musoke

Funding

Makerere Univ.-Johns Hopkins Univ. HIV Clinical Trials Unit-Kampala, UgandaU01AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FOWLER, MARY GLENN · 2007 to 2011
$25.8M
NIAID NIH HHS U01 AI069530
6 · The paper itself

Abstract

objectivesTo determine and compare the clinical and immunologic outcomes for HIV-infected women initiated on antiretroviral therapy (ART), with and without previous exposure to single-dose nevirapine in the MTCT-Plus programme - Kampala, Uganda, from 2003 to 2011.

methodsRetrospective comparison of prospectively collected programmatic data of clinical and immunologic treatment outcomes among HIV-infected Ugandan women, with and without prior exposure to sdNVP, who received NNRTI-based ART for a median follow-up of 6 years.

resultsOf the 408 women in the programme, 289 (70.8%) were started on ART, of whom 205 (70.9%) had prior exposure to sdNVP. Clinical, immunologic and combined (clinical and or immunologic) treatment failure occurred in 29 (10.0%), 132 (45.7%) and 142 (49.1%) women, respectively. There was no significant difference in the distribution of time to immunologic failure for women by exposure to sdNVP (log-rank P = 0.98). In Cox proportional hazard modelling, exposure to sdNVP was not associated with immunologic failure [adjusted hazard ratio (HR) = 0.89, 95% confidence interval (CI): 0.61-1.30]. CD4 count >100 cells/mm(3) at initiation was associated with reduced incidence of immunologic failure in adjusted analyses (HR = 0.32, 95% CI: 0.22-0.48).

conclusionsHIV-infected Ugandan women initiated on an NVP-based ART regimen had similar immunologic treatment outcomes irrespective of previous NVP exposure. CD4 cell count prior to initiating HAART was a key prognostic factor for successful long-term immunologic treatment outcomes. In poor settings, regular follow-up of patients on HAART with adequate counselling to promote adherence and safe disclosure may promote low clinical failure rates.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountFemaleFollow-Up StudiesHIV InfectionsHumansInfectious Disease Transmission, VerticalKaplan-Meier EstimateNevirapineProportional Hazards ModelsRetrospective StudiesTime FactorsTreatment FailureUgandaAnti-HIV AgentsNevirapine

Identifiers

PMID23289497
PMCPMC6746559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.